WINT on OTC

WINDTREE THERAPEUTICS INC /DE/

We are a biotechnology company focused on advancing early and late-stage innovative therapies for critical conditions and diseases.1

Price unavailable

Last updated Oct 19, 2026.

Overview

Compare with aTyr Pharma, Titan Pharmaceuticals or Abpro Holdings, Inc., or pick any stock.

  • TickerWINT on OTC1
  • IndustryBiological Products, (No Diagnostic Substances)1
  • HeadquartersWarrington, Pennsylvania1
  • Incorporated inDE2
  • Business address2600 Kelly Road, Suite 100, Warrington, Pa 189762
  • Filer categoryNon-accelerated filer, Smaller reporting company2

See how the biggest companies compare on our leaderboards

We are a biotechnology company focused on advancing early and late-stage innovative therapies for critical conditions and diseases. Our portfolio of product candidates includes istaroxime, a Phase 2 candidate that inhibits the sodium-potassium ATPase and also activates sarco endoplasmic reticulum Ca2+ -ATPase 2a, or SERCA2a, for acute heart failure and/or associated cardiogenic shock; preclinical SERCA2a activators for heart failure; rostafuroxin for the treatment of hypertension in patients with a specific genetic profile; and a preclinical atypical protein kinase C iota, or aPKCi, inhibitor (topical and oral formulations), being developed for potential application in rare and broad oncology indications. We also have a licensing business model with partnership out-licenses currently in place.3 From its latest annual report

Financials

From the company’s reports to the SEC. Every number links to the filing it came from.

Key numbers, fiscal 2019

-12572.2%Operating margin4
-13876.3%Net margin4
-88.9%Revenue growth, 20195
-36.7%Return on equity6
-$24.9MFree cash flow4

Where the money goes

Where each dollar of revenue went, fiscal 2019

  • Research and development50¢$12.7M
  • Selling, general and admin48¢$12.4M
  • Interest2¢$495.0K

Out of $198.0K in revenue.54 The company lost money this year.

Financial statements

Revenue5$198.0K in 2019−89% since 2018
0$500.0K$1.0M$1.5M$2.0M2018: $1.8M$1.8M20182019: $198.0K$198.0K2019−89%
Operating income54-$24.9M in 2019+54% since 2018
-$30.0M-$20.0M-$10.0M02018: -$16.2M-$16.2M20182019: -$24.9M-$24.9M2019+54%
Net income54-$27.5M in 2019+34% since 2018
-$30.0M-$20.0M-$10.0M02018: -$20.5M-$20.5M20182019: -$27.5M-$27.5M2019+34%
Fiscal year20182019
Revenue$1.8M5$198.0K5
Cost of revenue
Research and development$10.6M5$12.7M4
Selling, general and admin$7.4M5$12.4M4
Operating expenses
Operating income-$16.2M5-$24.9M4
Interest$1.4M5$495.0K4
Income before tax
Income tax
Net income-$20.5M5-$27.5M4
Earnings per share-$7.749
Earnings per share (diluted)-$7.749
Shares (weighted, basic)

Compare WINDTREE THERAPEUTICS INC /DE/ with another company

Leadership

Who has led WINDTREE THERAPEUTICS INC /DE/, and when. Pick a name to see everywhere that person has worked.

Chief executive

  1. Robert J. Capetola2006–2008
  2. W. Thomas Amick2009–2013
  3. Craig Fraser2016–now

Chair

  1. W. Thomas Amick2012

President

  1. Robert J. Capetola2006–2008
  2. Craig Fraser2016–now

Chief financial officer

  1. John A. Tattory2015–2023

Chief operating officer

  1. Christopher Schaber2006
  2. Eric Curtis2020–2023
2010201520202025
Board members and other officers (36)

Former names

  • DISCOVERY LABORATORIES INC /DE/Dec 5, 1997 to Apr 18, 20162
  • ANSAN PHARMACEUTICALS INCAug 26, 1997 to Jul 21, 19972
  • ANSAN INCSep 5, 1996 to May 15, 19962

Timeline

  1. Feb 2, 2016New chief executive Craig Fraser becomes CEO10
  2. Sep 8, 2009New chief executive W. Thomas Amick becomes CEO11
  3. Jan 5, 2006New chief executive Robert J. Capetola becomes CEO12

Filings

279 filings to the SEC since October 2021: 6 annual reports, 13 quarterly reports, 96 major events, 50 insider forms, 15 large holders, 99 other. The latest 20:

  1. Jul 22, 20268-K EDGAR
  2. Apr 1, 2026NT 10-K EDGAR
  3. Jan 7, 20268-K EDGAR
  4. Dec 2, 20258-K EDGAR
  5. Nov 21, 2025424B3 EDGAR
  6. Nov 19, 202510-Q EDGAR
  7. Nov 14, 2025NT 10-Q EDGAR
  8. Nov 13, 2025424B3 EDGAR
  9. Oct 24, 2025S-1 EDGAR
  10. Oct 16, 20258-K EDGAR
  11. Oct 6, 20258-K EDGAR
  12. Sep 8, 20258-K EDGAR
  13. Sep 2, 20258-K EDGAR
  14. Aug 20, 20258-K EDGAR
  15. Aug 19, 202510-Q EDGAR
  16. Aug 14, 2025NT 10-Q EDGAR
  17. Aug 11, 2025ARS EDGAR
  18. Aug 8, 2025DEF 14A EDGAR
  19. Aug 8, 20258-K EDGAR
  20. Aug 5, 20253 EDGAR

The 279 filings since October 2021 can be filtered by form type and year here when JavaScript is on.

Every filing from the last five years, summarized. The full record is on SEC EDGAR.

Insider trades

20 open-market trades by officers, directors and large owners since October 2021: 19 buys and 1 sales. Grants, option exercises and gifts are left out.

DateWhoTradeSharesPriceValueFiling
Oct 8, 2024Fraser CraigPresident and CEOBuy5,431$0.91$4.9KForm 4
Sep 27, 2023Fraser CraigPresident and CEOBuy2,500$1.02$2.5KForm 4
Sep 26, 2023Fraser CraigPresident and CEOBuy2,500$0.90$2.2KForm 4
Apr 26, 2023Fraser CraigPresident and CEOBuy1,497$1.77$2.6KForm 4
Apr 25, 2023Fraser CraigPresident and CEOBuy1,315$1.89$2.5KForm 4
Jul 27, 2022Fraser CraigPresident and CEOBuy2,500$0.38$950Form 4
Jul 26, 2022Hamill John P.SVP & CFOBuy3,000$0.37$1.1KForm 4
Jul 26, 2022Fraser CraigPresident and CEOBuy2,500$0.37$925Form 4
Jun 30, 2022Fraser CraigPresident and CEOBuy4,500$0.43$1.9KForm 4
Jun 29, 2022Fraser CraigPresident and CEOBuy7,000$0.42$2.9KForm 4
Mar 16, 2022Fraser CraigPresident and CEOBuy2,000$0.98$2.0KForm 4
Mar 15, 2022Simonson StevenSVP, Chief Medical OfficerBuy5,000$1.00$5.0KForm 4
Mar 15, 2022Fraser CraigPresident and CEOBuy3,000$0.98$2.9KForm 4
Dec 30, 2021Center Laboratories, Inc.10% ownerBuy1,239,088$1.60$2.0MForm 4
Dec 30, 2021Bioengine Capital Inc.10% ownerSale1,239,088$1.60$2.0MForm 4
Nov 19, 2021Fraser CraigPresident and CEOBuy930$1.60$1.5KForm 4
Nov 18, 2021Fraser CraigPresident and CEOBuy930$1.61$1.5KForm 4
Oct 22, 2021Fraser CraigPresident and CEOBuy3,000$1.90$5.7KForm 4
Oct 19, 2021Huang JamesDirectorBuy50,000$1.90$95.0KForm 4
Oct 19, 2021Fraser CraigPresident and CEOBuy3,000$1.91$5.7KForm 4

From Forms 4 filed with the SEC.

Major holders

Investors who own more than 5% of the shares must tell the SEC: a 13D if they may seek to influence the company, a 13G if they hold passively.

Sources

The numbers on this page point here. Each one links to the record it came from.

  1. 1
  2. 2
  3. 3
  4. 4
  5. 5
  6. 6
  7. 7
  8. 8
  9. 9
  10. 10
  11. 11
  12. 12
  13. 13
  14. 14
  15. 15
  16. 16
  17. 17
  18. 18
  19. 19
  20. 20
  21. 21
  22. 22
  23. 23
  24. 24
  25. 25
  26. 26
  27. 27
  28. 28
  29. 29
  30. 30
  31. 31
  32. 32
  33. 33
  34. 34
  35. 35
  36. 36
  37. 37
  38. 38
  39. 39
  40. 40
  41. 41
  42. 42
  43. 43
  44. 44
  45. 45
  46. 46
  47. 47
  48. 48
  49. 49
  50. 50
  51. 51
  52. 52
  53. 53
  54. 54
  55. 55
  56. 56
  57. 57
  58. 58